EMPAVELI®

(em-puh-vel-ee) Active ingredient(s): Pegcetacoplan (peg-set-a-koé-plan)

Consumer Medicine Information

This leaflet provides important information about using EMPAVELI. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using EMPAVELI.

Where to find information in this leaflet:

1. Why am I using EMPAVELI?

2. What should I know before I use EMPAVELI?

3. What if I am taking other medicines?

4. How do I use EMPAVELI? 5. What should I know while using EMPAVELI?

6. Are there any side effects?

7. Product details

1. Why am I using EMPAVELI?

EMPAVELI contains the active ingredient pegcetacoplan. EMPAVELI is a modified long-acting form of a peptide. Pegcetacoplan has been designed to attach to the C3 complement protein, which is a part of the body's defence system called the 'complement system'.

EMPAVELI is used to treat adult patients with a disease called paroxysmal nocturnal haemoglobinuria (PNH) who do not respond well enough to, or cannot take, a C5 inhibitor.

In patients with PNH, the 'complement system' is overactive and attacks their red blood cells, which can lead to low red blood counts (anaemia), tiredness, difficulty in functioning, pain, abdominal pain, dark urine, shortness of breath, difficulty swallowing, erectile dysfunction and blood clots.

EMPAVELI attaches to and blocks the C3 protein of the complement system. This stops the body's inflammatory response from attacking and destroying PNH red blood cells. In this way, EMPAVELI improves anaemia, fatigue and other signs and symptoms of PNH.